Cytoplasmic CD109 as an Adjunctive Immunohistochemical Marker for High-Grade Differentiated Thyroid Carcinoma Arising from Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

While immunohistochemical biomarkers are widely used to assist pathologic diagnosis, reliable adjunctive markers for high-grade differentiated thyroid carcinoma (HGDTC) and anaplastic thyroid carcinoma (ATC) remain limited. Based on our previous finding that CD109 is associated with the anaplastic transformation of papillary thyroid carcinoma (PTC), we evaluated CD109 expression across follicular cell-derived thyroid carcinomas to assess its utility as an adjunctive immunohistochemical marker. We analyzed 141 thyroid carcinoma cases, including 14 ATC, 29 HGDTC, 63 PTC (22 TERT promoter mutation-positive and 41 mutation-negative), 25 follicular thyroid carcinoma (FTC), and 10 poorly differentiated thyroid carcinoma (PDTC). Among the 29 HGDTC cases, 22 arose from PTC (HGDTC (PTC)) and 7 arose from FTC (HGDTC (FTC)). Using weak or strong cytoplasmic CD109 staining (C1+/C2+) as the cutoff, sensitivity exceeded 90% for HGDTC (PTC) and reached 100% for ATC to differentiate from PDTC, FTC, TERT promoter mutation-negative PTC, and HGDTC (FTC). Restricting positivity to strong cytoplasmic staining (C2+) increased specificity to > 95% for HGDTC (PTC), ATC, and TERT promoter mutation-positive PTC, suggesting that CD109 may be useful as an adjunct biomarker in diagnosing HGDTC (PTC) and ATC. In a parsimonious multivariable analysis, ATC remained associated with C2 + expression after adjustment for age, sex, and Ki-67 labeling index. Overall, strong cytoplasmic CD109 expression is enriched in ATC and may provide supportive evidence for HGDTC (PTC) or anaplastic transformation when interpreted together with morphology.

Authors

Institutions

Publication Details

Journal
Endocrine Pathology
Published
2026-11-18
DOI
https://doi.org/10.1007/s12022-026-09942-y
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytoplasmic CD109 as an Adjunctive Immunohistochemical Marker for High-Grade Differentiated Thyroid Carcinoma Arising from Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Yuki Matsuoka, Hiroyuki Yamashita, Hirokazu Kurohama, Hisakazu Shindo et al.
1 links
Endocrine Pathology
Thyroid Cancer Diagnosis and Treatment
article

Cytoplasmic CD109 as an Adjunctive Immunohistochemical Marker for High-Grade Differentiated Thyroid Carcinoma Arising from Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Yuki Matsuoka, Hiroyuki Yamashita, Hirokazu Kurohama, Hisakazu Shindo, Kasumi Kawamura, Masahiro Nakashima, Ichiro Horie, Mayu Ueda, Katsuya Matsuda, Shinya Satoh, Adiya Kerimbayeva, Tomoko Cohen, Keiji Suzuki
article en

Abstract

While immunohistochemical biomarkers are widely used to assist pathologic diagnosis, reliable adjunctive markers for high-grade differentiated thyroid carcinoma (HGDTC) and anaplastic thyroid carcinoma (ATC) remain limited. Based on our previous finding that CD109 is associated with the anaplastic transformation of papillary thyroid carcinoma (PTC), we evaluated CD109 expression across follicular cell-derived thyroid carcinomas to assess its utility as an adjunctive immunohistochemical marker. We analyzed 141 thyroid carcinoma cases, including 14 ATC, 29 HGDTC, 63 PTC (22 TERT promoter mutation-positive and 41 mutation-negative), 25 follicular thyroid carcinoma (FTC), and 10 poorly differentiated thyroid carcinoma (PDTC). Among the 29 HGDTC cases, 22 arose from PTC (HGDTC (PTC)) and 7 arose from FTC (HGDTC (FTC)). Using weak or strong cytoplasmic CD109 staining (C1+/C2+) as the cutoff, sensitivity exceeded 90% for HGDTC (PTC) and reached 100% for ATC to differentiate from PDTC, FTC, TERT promoter mutation-negative PTC, and HGDTC (FTC). Restricting positivity to strong cytoplasmic staining (C2+) increased specificity to > 95% for HGDTC (PTC), ATC, and TERT promoter mutation-positive PTC, suggesting that CD109 may be useful as an adjunct biomarker in diagnosing HGDTC (PTC) and ATC. In a parsimonious multivariable analysis, ATC remained associated with C2 + expression after adjustment for age, sex, and Ki-67 labeling index. Overall, strong cytoplasmic CD109 expression is enriched in ATC and may provide supportive evidence for HGDTC (PTC) or anaplastic transformation when interpreted together with morphology.

Endocrine PathologyVol. 37(1)
Nagasaki University (JP), Yamashita Thyroid Hospital (JP), Atomic Bomb Disease Institute, Nagasaki University (JP)
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon